Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Elan 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Elan 1Q

Biopharmaceutical business revenue was up 28% driven by Tysabri sales, offsetting reduced sales of Azactam and Maxipime.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 1Q

1Q Revenues: $245.1 million (+14%)

1Q Loss: $102.6 million (loss of $85.5 million in 1Q08)

Comments: Biopharmaceutical business revenue was up 28% driven by Tysabri sales, offsetting reduced sales of Azactam and Maxipime. Elan recorded $158.7 million of Tysabri sales (+48%) in the quarter. Revenue from the Elan Drug Technologies (EDT) business dropped 14%, due to timing differences of milestone payments earned and customer orders. The increase in losses primarily relates to severance and restructuring charges of $22.2 million and non-cash asset impairment charges of $15.4 million. These charges relate to the previously announced postponement of Elan’s biologics manufacturing activities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters